Search Results
Your search for all items matches 34490 pages
Showing 1 - 50Two Initiatives Could Help Increase Oncogene Testing in Primary Care Settings
Investigators may have identified new strategies for use in the primary care setting to improve the detection of cancer-susceptibility genes, according to a recent study published by Swisher et al in JAMA Network Open. Background Up to 10% of cancers—including breast cancer, ovarian cancer,...
Liquid Biopsies Could Help Guide Colorectal Cancer Treatment
The use of a circulating tumor DNA (ctDNA) liquid biopsy to guide colorectal cancer treatment in the adjuvant setting may not compromise outcomes despite allowing many patients to avoid chemotherapy, according to a recent study published by Tie et al in Nature Medicine. Background A liquid biopsy...
Addition of ADT to SBRT in Hormone-Sensitive Oligorecurrent Prostate Cancer
In an Italian single-center phase II trial (RADIOSA) reported in The Lancet Oncology, Marvaso et al found that the addition of androgen-deprivation therapy (ADT) to stereotactic body radiotherapy (SBRT) improved progression-free survival in patients with hormone-sensitive oligorecurrent prostate...
Two Decades of Collaboration: The Accelerating Anticancer Agent Development and Validation (AAADV) Workshop
Over the past 20 years, the investment in research and development of cancer therapies has been unprecedented, and the pace of new drug development has been accelerating. To illustrate this trajectory, the U.S. Food and Drug Administration (FDA) approved 71 treatments for solid cancers in adults...
Cancer Incidence and Mortality in Southeast Asia for 2022
In a study reported in The Lancet Oncology, Dee et al identified cancer incidence and mortality rates for 2022 in the countries of southeast Asia. Study Details The study involved data from the GLOBOCAN 2022 database developed by the International Agency for Research on Cancer for the 11 countries...
Novel Nanoliposome Radiotherapeutic May Enhance Survival in Patients With Glioblastoma
The investigational drug formulation rhenium (Re)-186 obisbemeda (RNL-186) may extend survival in patients with glioblastoma, according to a recent study published by Brenner et al in Nature Communications. Background Glioblastoma is the most common primary brain tumor in adult patients. The median ...
Chemoimmunotherapy Approach for Advanced HPV-Negative Head and Neck Cancer
Combining the PD-1 inhibitor nivolumab and chemotherapy, and following that regimen with response-adapted chemoradiation, may an effective treatment for advanced human papillomavirus (HPV)-negative head and neck squamous cell carcinoma, according to a recent study published by Rosenberg et al in...
Digital Integrative Medicine Intervention for Patients Undergoing Active Cancer Treatment
Cancer and its treatments often contribute to burdensome symptoms that negatively impact patients’ quality of life and treatment outcomes, including fatigue, anxiety, and depression.1 Many patients experience multiple symptoms concurrently2 that can disrupt their treatments and lead to unplanned...
Clonal and Subclonal Pathogenic Alterations at Diagnosis in High-Risk Neuroblastoma
In a Children’s Oncology Group (COG) study reported in the Journal of Clinical Oncology, Berko et al identified the spectrum and clinical significance of clonal and subclonal pathogenic alterations in high-risk neuroblastoma. Study Details The study involved use of a focused high-risk neuroblastoma ...
ACS Awards Dr. W. Kimryn Rathmell the 2025 Medal of Honor
In recognition of her commitment to tackling the complexities and challenges of cancer, the American Cancer Society (ACS) awarded the 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, MMHC. The Medal of Honor is the American Cancer Society’s most prestigious award given to distinguished...
Discussing Breast Density With Patients Following the FDA Mammography Quality Standards Act Mandate
In JAMA, Lee et al provided a concise, evidence-based summary to help clinicians discuss information regarding breast density and implement shared decision-making with patients following the U.S. Food and Drug Administration (FDA) Mammography Quality Standards Act mandate. Since September 2024,...
Greater Plant-Based Oil, Lower Butter Intake Could Improve Risk of Cancer-Related Mortality
Investigators have found that the consumption of plant-based oils instead of butter may provide beneficial health effects and potentially reduce the risk of premature mortality, according to recent findings presented at the American Heart Association Epidemiology, Prevention, Lifestyle &...
Breast Cancer Mortality Rates May Have Stopped Declining
Breast cancer mortality rates may have stopped declining in women older than 74 years and younger than 40 years, according to a recent study published by Monticciolo and Hendrick in the Journal of Breast Imaging. Background Breast cancer is the second leading cause of cancer-related mortality among ...
How the Cancer Moonshot Is Making a Difference for Patients Here and Across the World
Catharine Young, PhD, has spent the past decade of her career focused on cancer policy and advocacy. A native of Johannesburg, South Africa, Dr. Young served as Senior Director of Science Policy at the Biden Cancer Initiative, which began in 2017 by then former Vice President Joe Biden. There she...
Partial-Gland Removal May Be an Option for Many Men With Prostate Cancer
A 5-year study on men that had primary partial-gland cryoablation shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual function. Led by researchers at New York University Grossman School of Medicine, the study tracked the patient outcomes after...
SGLT2 Inhibitors Could Help Protect Against Heart Failure in Patients With Cancer
A common type of diabetes drug known as sodium-glucose cotransporter-2 (SGLT2) inhibitors could help patients with cancer achieve greater long-term recovery, according to a novel study published by Bhalraam et al in the European Journal of Preventive Cardiology. Background Many patients with cancer ...
Genetic Factors Could Illuminate Which Patients With Prostate Cancer Could Benefit From Combination of Ipatasertib Abiraterone
Researchers have uncovered several biomarkers that may predict how patients with metastatic castration-resistant prostate cancer will respond to the novel combination of ipatasertib and abiraterone, according to a recent study published by Bono et al in European Urology. Background Prostate cancer...
Outcomes After Complete Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma
In a retrospective study reported in JAMA Network Open, Lim et al found that complete response to immunotherapy as first-line treatment of advanced hepatocellular carcinoma was associated with good outcomes. Study Details The study involved analysis of 228 patients who received atezolizumab and...
Can Plasma ctDNA Kinetics Predict Response to Systemic Therapy in Advanced NSCLC?
In a systematic review and meta-analysis reported in The Oncologist, Leite da Silva et al found plasma circulating tumor DNA (ctDNA) kinetics to be predictive of survival outcomes in patients with advanced non–small cell lung cancer (NSCLC) who were undergoing targeted therapy and immune checkpoint ...
Combination of Immunotherapies for Advanced HPV-Associated Cancers
In a single-center phase I/II trial reported in JAMA Oncology, Floudas et al found that the combination of the human papillomavirus (HPV) type 16 therapeutic vaccine PDS0101, the tumor-targeting interleukin-12 antibody-drug conjugate PDS01ADC, and the bifunctional PD-L1/TGF-β inhibitor bintrafusp...
Novel Biomarkers May Improve Diagnosis of Gallbladder Cancer
Plasma proteins may be capable of distinguishing gallbladder cancer from cholecystitis, which could reduce unnecessary procedures and improve treatment options in patients with suspected gallbladder cancer, according to a recent study published by Nouairia et al in JHEP Reports. Gallbladder cancer...
Consumer Survey Reveals Common Misconceptions About HPV and HPV-Related Cancer
A large proportion of individuals may be unaware of the risk of human papillomavirus (HPV) infections and cancer among men, according to a recent consumer survey commissioned by The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research...
MRD-Based Endpoint to Support Accelerated Approval of Treatment for Multiple Myeloma
In a pooled analysis reported in the Journal of Clinical Oncology, Shi et al found that a clinical trial endpoint of complete response with minimal residual disease (also known as measurable residual disease) at the 10-5 threshold (MRD-CR) at 9 or 12 months could be used to support accelerated...
Trastuzumab Rezetecan in Advanced HER2-Positive NSCLC
In a Chinese phase II trial (HORIZON-Lung) reported in The Lancet Oncology, Li et al found that trastuzumab rezetecan, a novel antibody-drug conjugate, showed activity in patients with advanced HER2-positive non–small cell lung cancer (NSCLC). Trastuzumab rezetecan consists of a HER2-directed...
Overcoming Resistance to KRAS G12C Inhibitors in Pancreatic and Colorectal Cancers
A study evaluating the genetic landscape of candidate primary resistance alterations relevant to KRAS targeting in KRAS G12C–mutant colorectal cancers and pancreatic ductal adenocarcinomas (PDAC) has found that putative resistance alterations are prevalent in these cancers. The finding may explain...
MSTFCRC Updates Recommendations for Colonoscopy Preparation
Updated consensus recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer (MSTFCRC) address optimizing the quality of bowel preparation for colonoscopy. The document, published today by Jacobson et al, presents clinical strategies to improve bowel preparation as they apply...
Postradiotherapy Survival in Patients With Glioblastoma Multiforme and Low-Grade Gliomas
Investigators may have uncovered how radiotherapy affects survival in patients with glioblastoma multiforme and low-grade glioma, according to a recent study published by Veviorskiy et al in Aging. The findings highlighted key biological differences between these cancer types. Background...
Is There a Link Between Tattoos and Increased Cancer Risk?
Skin cancers and lymphoma may be more prevalent among individuals with tattoos compared with those without tattoos, according to a recent study published by Clemmensen et al in BMC Public Health. Prior research has shown that tattoo ink does not just remain at the site of injection—instead, when...
Prophylactic Strategy for Preventing Infusion-Related Reactions With IV Amivantamab in EGFR-Mutated NSCLC
Based on results from the phase II SKIPPirr trial, the addition of 8 mg of dexamethasone to standard infusion-related reaction prophylaxis appeared to reduce the incidence of such events by approximately threefold in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who were...
Clinical Characteristics of Breast Cancer in Young BRCA Carriers
In a study reported in the Journal of Clinical Oncology, Matteo Lambertini, MD, and colleagues identified clinical characteristics of breast cancer in young women carrying germline pathogenic variants in BRCA1 vs BRCA2 and examined the effect of prediagnostic BRCA testing on outcomes. Study...
Francis S. Collins, MD, PhD, Retires From the National Institutes of Health
Francis S. Collins, MD, PhD, announced in a statement his retirement as Director of the National Institutes of Health (NIH), effective February 28, 2025. Dr. Collins is the longest-serving presidentially appointed NIH Director, having served three U.S. presidents over more than 12 years—Barack...
Novel Prediction Score May Estimate Risk of Early-Onset Colorectal Cancer, Precancerous Polyps
Researchers have developed and validated a novel prediction model that may be capable of estimating the risk of colorectal cancer and advanced precancerous polyps in patients younger than 45 years, according to a recent study published by Wehbe et al in Digestive Diseases and Sciences. Background...
Chemotherapy, Endocrine Therapy May Have Different Long-Term Physical Health Effects in Breast Cancer Survivors
The receipt of chemotherapy or endocrine therapy without chemotherapy could be associated with different long-lasting physical health declines among breast cancer survivors compared with those without breast cancer, according to a recent study published in JAMA Network Open. Background Physical...
Idecabtagene Vicleucel vs Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
In a retrospective study reported in the Journal of Clinical Oncology, Hansen et al found that standard-of-care ciltacabtagene autoleucel was associated with better efficacy outcomes and increased risk of some toxicities vs standard-of-care idecabtagene vicleucel in patients with relapsed or...
Final Results of LIBRETTO-001: Selpercatinib in RET Fusion–Positive NSCLC
As reported in the Journal of Clinical Oncology by Gautschi et al, final results of the registrational phase I/II LIBRETTO-001 trial showed continued benefit of selpercatinib in patients with RET fusion–positive non–small cell lung cancer (NSCLC). Study Details The primary analysis of the trial...
Palbociclib Plus Endocrine Therapy vs Capecitabine in HR-Positive, HER2-Negative Metastatic Breast Cancer
In an overall survival analysis of a South Korean phase II trial (Young-PEARL) reported in The Lancet Oncology, Ahn et al found no benefit with palbociclib plus exemestane and leuprorelin vs capecitabine in premenopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast...
The Importance of Diversity in Clinical Research
The Cancer Drug Development Forum (CDDF) held its annual conference in the Netherlands from February 3–5, 2025. Under the title “Challenges, Advances, and Open Questions in Global Cancer Drug Development and Clinical Trials,” the workshop focused on diversity and real-world evidence in anticancer...
Combination of MCL-1 and SRC Inhibitors May Increase Cell Death in AML
An innovative combination of treatment strategies involving myeloid cell leukemia (MCL)-1 inhibitors and a kinase inhibitor targeting the SRC oncogene could be effective at triggering cell death in acute myeloid leukemia (AML) cells, according to a recent study published by Hu et al in Signal...
Decoding Varying Risk of Colorectal Cancer Among Different Steatotic Liver Disease Subgroups
Investigators have found that the risk of colorectal cancer may vary among steatotic liver disease subgroups and could be higher in patients with alcoholic liver disease, according to a recent study published by Kimura et al in Clinical Gastroenterology and Hepatology. Background Lifestyle-related...
Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
It’s a fast-paced world, no two ways about it. People move on from one event to another. We have to move on either for our own sake or the sake of someone near and dear. In the medical field, patients come and go, surgeries are performed, treatments are given, and everybody moves on. Being kind to...
7-Year Follow-up of ABC Trial: Ipilimumab/Nivolumab vs Nivolumab Alone in Melanoma Brain Metastases
As reported in The Lancet Oncology by Long et al, 7-year follow-up of the Australian phase II ABC trial showed continued benefit of ipilimumab/nivolumab vs nivolumab alone in patients with asymptomatic melanoma brain metastases. Study Details In the open-label multicenter study, 63...
Testosterone Recovery After Androgen-Deprivation Therapy Linked to Improved Survival in High-Risk Prostate Cancer
Testosterone recovery to normal levels after long-term term androgen-deprivation therapy and radiotherapy significantly improved overall survival in patients with high-risk prostate cancer, according to data presented at the 2025 ASCO Genitourinary Cancers Symposium.1 Long-term data from the phase...
Breast-Conserving Surgery Linked to Improved Sexual Well-Being Compared With Postmastectomy Breast Reconstruction
Breast-conserving therapy may be associated with improved sexual well-being compared with mastectomy followed by breast reconstruction in patients with breast cancer, according to a recent study published by Stern et al in Plastic and Reconstructive Surgery. Background Many patients with breast...
Bacterial Leakage Across Gastric Lining Could Signify Cancer Risk
Researchers may have uncovered insights into the role of bacteria in the development of gastric cancer, according to a novel study published by Giddings et al in Helicobacter. The findings could pave the way for a more effective precancer treatment option. Background Gastric cancer is the fourth...
ASTRO Issues Clinical Guideline on Radiation Therapy for Anal Cancer
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary squamous cell carcinoma of the anal canal and anal margin. The guideline, ASTRO’s first for anal cancer, is published in...
Overall Survival and HRQOL with Addition of [177Lu]Lu-PSMA-617 to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
In an analysis of an Australian phase II trial (ENZA-p) reported in The Lancet Oncology, Emmett et al reported that the addition of lutetium-177–labeled PSMA-617 (LuPSMA) to enzalutamide improved overall survival and several aspects of health-related quality of life (HRQOL) in the first-line...
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early HER2-Positive Breast Cancer
In an analysis from the ShortHER trial reported in JAMA Oncology, Dieci et al identified 10-year outcomes with 9 weeks or 1 year of adjuvant trastuzumab plus chemotherapy according to level of tumor-infiltrating lymphocytes (TILs) in patients with early HER2-positive breast cancer. Study Details...
Top Picks From SABCS 2024
Among the high-quality abstract presentations at the 2024 San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCO Post asks our Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman...
Cabozantinib/Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma
In a multicohort phase Ib study (COSMIC-021) reported in the Journal of Clinical Oncology, Sumanta K. Pal, MD, FASCO, and colleagues identified the activity of cabozantinib plus atezolizumab in a cohort of patients with locally advanced or metastatic urothelial carcinoma according to first-line...
Participation in Early Trials May Provide Some Patients With Access to Cancer Drugs Later FDA Approved
Nearly 20% of patients participating in middle-stage cancer drug trials may receive treatments that eventually receive U.S. Food and Drug Administration (FDA) approval, according to a recent study published by Ouimet et al in the Journal of the National Cancer Institute. The findings may have...
